Heuristics of human enhancement risk: A little chemical help?

International Journal of Health Promotion and Education

Volumn 51, Issue 4, 2013, Pages 212-227

  Brennan, Rebekah ^a   Van Hout, Marie Claire ^a   Wells, John ^a  

^a Ireland   (Ireland)

Author keywords

growth hormones; human enhancement drugs; injecting drug use (IDU); site enhancement oils; tanning agents

Indexed keywords

AFAMELANOTIDE; ANDROGEN; BOTULINUM TOXIN A; COSMETIC; MELANOTAN II; SILICON;

ARTICLE; CONSUMER HEALTH INFORMATION; COST BENEFIT ANALYSIS; HEALTH EDUCATION; HEALTH HAZARD; HUMAN; PEER GROUP; PUBLIC HEALTH; RISK ASSESSMENT;

EID: 84882982053     PISSN: 14635240     EISSN: 21649545     Source Type: Journal    
DOI: 10.1080/14635240.2013.818295     Document Type: Article

References (161)

1. ACMD (Advisory Council on the Misuse of Drugs). 2010. Consideration of the Anabolic Steroids, London: ACMD.
2. Aitken, C., Delalande, C., and, Stanton, K. 2002. Pumping Iron, Risking Infection? Exposure to Hepatitis C, Hepatitis B and HIV among Anabolic-Androgenic Steroid Injectors in Victoria, Australia. Drug and Alcohol Dependence, 65: 303-308.
3. Bacchi, C., and, Beasley, C. 2002. Citizen Bodies: Is Embodied Citizenship a Contradiction in Terms?. Critical Social Policy, 22 (2): 324-352.
4. Bagshaw, S. M., McAlister, F. A., Manns, B. J., and, Ghali, W. A. 2006. Acetylcysteine in the Prevention of Contrast-Induced Nephropathy: A Case Study of the Pitfalls in the Evolution of Evidence. Archives of Internal Medicine, 166: 161-166.
5. Bailey, L. 2005. Control and Desire: The Issue of Identity in Popular Discourses of Addiction. Addiction Research and Theory, 13: 535-543.
6. Baker, J. S., Graham, M. R., and, Davies, B. 2006. Steroid and Prescription Medicine Abuse in the Health and Fitness Community: A Regional Study. European Journal of Internal Medicine, 17: 479-484.
7. Banke, I. J., Prodinger, P. M., Waldt, S., Weirich, G., Holzapfel, B. M., Gradinger, R., and, Rechl, H. 2012. Irreversible Muscle Damage in Bodybuilding Due to Long-Term Intramuscular Oil Injection. International Journal of Sports Medicine, 33: 829-834.
8. Baume, N., Mahler, N., Kamber, M., Mangin, P., and, Saugy, M. 2006. Research of Stimulants and Anabolic Steroids in Dietary Supplements. Scandinavian Journal of Medicine & Science in Sports, 16: 41-48.
9. Baym, N. 2010. Personal Connections in the Digital Age, Cambridge: Polity Press.
10. Becker, M. H. 1974. The Health Belief Model and Personal Health Behaviour, Thorofare, NJ: Slack.
11. Benkler, Y. 2007. The Wealth of Networks: How Social Production Transforms Markets and Freedom, New Haven, CT: Yale University Press.
12. Bergeron, D., and, Tylka, T. L. 2007. Support for the Uniqueness of Body Dissatisfaction from Drive for Muscularity among Men. Body Image, 4: 288-295.
13. Boase, J., Horrigan, J. B., Wellman, B., and, Rainie, L. 2006. The Strength of Internet Ties, Washington, DC: Pew Internet & American Life Project.
14. Bolding, G., Sherr, L., and, Elford, J. 2002. Use of Anabolic Steroids and Associated Health Risks among Gay Men Attending London Gyms. Addiction, 97: 195-203.
15. Bolding, G., Sherr, L., Maguire, M., and, Elford, J. 1999. HIV Risk Behaviours among Gay Men Who Use Anabolic Steroids. Addiction, 94: 1829-1835.
16. Brower, K. J., Blow, F. C., Beresford, T. P., and, Fuelling, C. 1989. Anabolic-Androgenic Steroid Dependence. Journal of Clinical Psychiatry, 50: 31-33.
17. Bunton, R. 2001. Knowledge, Embodiment and Neo-Liberal Drug Policy. Contemporary Drug Problems, 28: 221-243.
18. Burgess, J., and, Green, J. 2009. YouTube, Cambridge: Polity Press.
19. Cafri, G., Thompson, J. K., Ricciardelli, L., McCabe, M., Smolak, L., and, Yesalis, C. 2005. Pursuit of the Muscular Ideal: Physical and Psychological Consequences and Putative Risk Factors. Clinical Psychology Review, 25: 215-239.
20. Cash, T. F., and, Smolak, L., eds. 2011. Body Image: A Handbook of Science, Practice, and Prevention, New York: Guilford Press.
21. Christiansen, A. V., and, Møller, J. 2012. Will Steroids Kill Me if I Use Them Once? A Qualitative Analysis of Inquiries Submitted to the Danish Anti-Doping Authorities. Performance Enhancement & Health, 1: 39-47.
22. Clark, R. P., and, Berris, C. E. 1989. Botulinum Toxin: A Treatment for Facial Asymmetry Caused by Facial Nerve Paralysis. Plastic and Reconstructive Surgery, 84 (2): 353-355.
23. Clark, R. F., Cantrell, F. L., Pacal, A., Chen, W., and, Betten, D. P. 2008. Subcutaneous Silicone Injection Leading to Multi-System Organ Failure. Clinical Toxicology (Philadelphia), 46 (9): 834-837.
24. Clement, C. L., Marlowe, D. B., Patapis, N. S., Festinger, D. S., and, Forman, R. F. 2012. Nonprescription Steroids on the Internet. Substance Use & Misuse, 47: 329-341.
25. Conrad, P. 2007. The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders, Baltimore, MD: Johns Hopkins University Press.
26. Copeland, J., Peters, R., and, Dillon, P. 2000. Anabolic-Androgenic Steroid Use Disorders among a Sample of Australian Competitive and Recreational Users. Drug and Alcohol Dependence, 60: 91-96.
27. Cordaro, F. G., Lombardo, S., and, Cosentino, M. 2011. Selling Androgenic Anabolic Steroids by the Pound: Identification and Analysis of Popular Websites on the Internet. Scandinavian Journal of Medicine and Science in Sports, 21 (6): e247-e257.
28. Coté, T. R., Mohan, A. K., Polder, J. A., Walton, M. K., and, Braun, M. M. 2005. Botulinum Toxin Type A Injections: Adverse Events Reported to the US Food and Drug Administration in Therapeutic and Cosmetic Cases. Journal of the American Academy of Dermatology, 53 (3): 407-415.
29. Cousen, P., Colver, G., and, Helbling, I. 2009. Eruptive Melanocytic Naevi Following Melanotan Injection. British Journal of Dermatology, 161: 707-708.
30. Currier, N., Solomon, S. E., and, Demicco, E. G. 2005. Oncogenic Signalling Pathways Activated in DMBA-Induced Mouse Mammary Tumors. Toxicologic Pathology, 33: 726-737.
31. Darsow, U., Bruckbauer, H., Worret, W. I., Hofmann, H., and, Ring, J. 2000. Subcutaneous Oleomas Induced by Self-Injection of Sesame Seed Oil for Muscle Augmentation. Journal of the American Academy of Dermatology, 42: 292-294.
32. Di Benedetto, G., Pierangeli, M., Scalise, A., and, Bertani, A. 2002. Paraffin Oil Injection in the Body: An Obsolete and Destructive Procedure. Annals of Plastic Surgery, 49: 391-396.
33. Dodge, T., and, Hoagland, M. F. 2011. The Use of Anabolic Androgenic Steroids and Polypharmacy: A Review of the Literature. Drug and Alcohol Dependence, 114 (2-3): 100-109.
34. Dorr, R. T., Ertl, G., Levine, N., Brooks, C., Bangert, J. L., and, Powell, M. B. 2004. Effects of a Super Potent Melanotropic Peptide in Combination with Solar UV Radiation on Tanning of the Skin Inhuman Volunteers. Archives of Dermatology, 140: 27-35.
35. Dorr, R. T., Lines, R., Levine, N., Xiang, L., Hruby, V. J., and, Hadley, M. E. 1996. Evaluation of Melanotan-II, a Super Potent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study. Life Sciences, 58: 1777-1784.
36. Downie, R. S., Tannahill, C., and, Tannahill, A. 2000. Health Promotion Models and Values, Oxford: Oxford University Press.
37. Duncan, S. C., Duncan, T. E., and, Strycker, L. A. 2002. A Multilevel Analysis of Neighborhood Context and Youth Alcohol and Drug Problems. Prevention Science, 3: 125-133.
38. Dutton, W. H., and, Blank, G. 2011. Next Generation Users: The Internet in Britain (Oxford Internet Survey 2011), Oxford: University of Oxford.
39. Edwards, P. C., and, Fantasia, J. E. 2007. Review of Long-Term Adverse Effects Associated with the Use of Chemically-Modified Animal and Non Animal Source Hyaluronic Acid Dermal Fillers. Journal of Clinical Interventions on Aging, 2 (4): 509-519.
40. Eisenach, J. H., Atkinson, J. L., and, Fealey, R. D. 2005. Hyperhidrosis: Evolving Therapies for a Well-Established Phenomenon. Mayo Clinic Proceedings, 80: 657-66.
41. Evans, N. 2004. Current Concepts in Anabolic-Androgenic Steroids. The American Journal of Sports Medicine, 32: 534-542.
42. Evans-Brown, M., Dawson, R. T., Chandler, M., and, McVeigh, J. 2009. Use of Melanotan I and II in the General Population. British Medical Journal, 338: b566
43. Evans-Brown, M., Kimergård, A., and, McVeigh, J. 2009. Elephant in the Room? The Methodological Implications for Public Health Research of Performance-Enhancing Drugs Derived from the Illicit Market. Drug Test Analysis, 1: 323-326.
44. Evans-Brown, M., and, McVeigh, J. 2009. Injecting Human Growth Hormone as a Performance-Enhancing Drug-Perspectives from the United Kingdom. Journal of Substance Use, 14: 267-288.
45. Evans-Brown, M., McVeigh, J., Perkins, C., and, Bellis, M. A. 2012. Human Enhancement Drugs: The Emerging Challenges to Public Health, Liverpool: Public Health Observatories in England.
46. Falck, R. S., Carlson, R. G., Wang, J., and, Siegal, H. A. 2004. Sources of Information about MDMA (3,4-Methylenedioxymethamphetamine): Perceived Accuracy, Importance, and Implications for Prevention among Young Adult Users. Drug and Alcohol Dependence, 74: 45-54.
47. Feick, J., and, Werle, R. 2010. " Regulation of Cyberspace ". In The Oxford Handbook of Regulation, Edited by: Cave, M., Baldwin, R. and Lodge, M. 523-547. Oxford: Oxford University Press.
48. Ferrandiz-Pulido, C., Fernandez-Figueras, M. T., Quer, A., and, Ferrandiz, C. 2011. An Eruptive Pigmented Lesion after Melanotan Injection. Clinical and Experimental Dermatology, 36: 801-802.
49. Fitzgerald, L. M., Fryer, J. L., Dwyer, T., and, Humphrey, S. M. 2006. Effect of MELANOTAN®, [Nle4, d-Phe7]-MSH, on Melanin Synthesis in Humans with MC1R Variant Alleles. Peptides, 27: 388-394.
50. Forman, R. F., Woody, G. E., McLellan, T., and, Lynch, K. G. 2006. The Availability of Web Sites Offering to Sell Opioid Medications without Prescriptions. American Journal of Psychiatry, 163: 1233-1238.
51. Fraser, R., Gower, D. B., Honour, J. W., Ingram, M. C., Kicman, A. T., Makin, H. L. J., and, Stewart, P. 2010. Analysis of Corticosteroids: Steroid Analysis, London: Springer.
52. Furlong, A., and, Cartmel, F. 1997. Young People and Social Change: Individualization and Risk in Late Modernity, Buckingham: Open University Press.
53. Gagnon, M., Jacob, J. D., and, Holmes, D. 2010. Governing through (In)Security: A Critical Analysis of a Fear Based Public Health Campaign. Critical Public Health, 20 (2): 245-256.
54. Georgieva, J., Assaf, C., Steinhoff, M., Treudler, R., Orfanos, C. E., and, Geilen, C. C. 2003. Bodybuilder Oleoma. British Journal of Dermatology, 149: 1289-1290.
55. Ghandourah, S., Hofer, M. J., Kießling, A., El-Zayat, B., and, Schofer, M. D. 2012. Painful Muscle Fibrosis Following Synthol Injections in a Bodybuilder: A Case Report. Journal of Medical Case Reports, 6 (1): 248
56. Glicenstein, J. 2007. The First Fillers, Vaseline and Paraffin. From Miracle to Disaster. Annales Chirurgie Plastique et Esthetique, 52: 157-161.
57. Glover-Thomas, N., and, Fanning, J. 2010. Medicalisation: The Role of E-Pharmacies in Iatrogenic Harm. Medical Law Review, 18: 28-55.
58. Gordon, S. M., Forman, R. F., and, Siatkowski, C. 2006. Knowledge and Use of the Internet as a Source of Controlled Substances. Journal of Substance Abuse Treatment, 30: 271-274.
59. Green, S., and J. Higgins. 2005. "Glossary." In Cochrane Handbook for Systematic Reviews of Interventions 4.2.5, The Cochrane Collaboration. Accessed October 19, 2012. http://www.cochrane.org/resources/ glossary.htm
60. Grogan, S. 2007. Body Image: Understanding Body Dissatisfaction in Men, Women and Children, East Sussex: Routledge.
61. Grogan, S., Shepherd, S., Evans, R., Wright, S., and, Hunter, G. 2006. Experiences of Anabolic Steroid Use. Journal of Health Psychology, 11 (6): 845-956.
62. Hadley, M. E., and, Dorr, R. T. 2006. Melanocortin Peptide Therapeutics: Historical Milestones. Clinical Studies and Commercialization. Peptides, 27: 921-930.
63. Halavais, A. 2008. Search Engine Society, Cambridge: Polity Press.
64. Handelsman, D. J. 2011. Commentary: Androgens and Anabolic Steroids: The One-Headed Janus. Endocrinology, 152: 1752-1754.
65. Hariri, L. P., Gaissert, H. A., Brown, R., Ciaranello, A., Greene, R. E., Selig, M. K., and, Kradin, R. L. 2012. Progressive Granulomatous Pneumonitis in Response to Cosmetic Subcutaneous Silicone Injections in a Patient with HIV-1 Infection: Case Report and Review of the Literature. Archives of Pathology and Laboratory Medicine, 136 (2): 204-207.
66. Hassan, R. 2008. The Information Society, Cambridge: Polity Press.
67. Haupt, H. A. 1993. Anabolic Steroids and Growth Hormone. American Journal of Sports Medicine, 21 (3): 468-474.
68. Henriksen, T. F., Løvenwald, J. B., and, Matzen, S. H. 2010. Paraffin Oil Injection in Bodybuilders Calls for Preventive Action. [In Danish.] UgeskrLaeger, 172: 219-220.
69. Hildebrandt, T., Alfano, L., and, Langenbucher, J. W. 2010. Body Image Disturbance in 1000 Male Appearance and Performance Enhancing Drug Users. Journal of Psychiatric Research, 44: 841-846.
70. Ip, E. J., Barnett, M. J., Tenerowicz, M. J., and, Perry, P. J. 2011. The Anabolic 500 Survey: Characteristics of Male Users versus Nonusers of Anabolic-Androgenic Steroids for Strength Training. Pharmacotherapy, 31 (8): 757-766.
71. Iversen, L., Lemcke, A., Bitsch, M., and, Karlsmark, T. 2009. Compression Bandage as Treatment for Ulcers Induced by Intramuscular Self-Injection of Paraffin Oil. Acta Dermato Venereoliga, 89: 196-197.
72. Jecker, N. 2011. Bioethics, 3rd ed., London: Jones & Bartlett.
73. Jones, L., Bates, G., Bellis, M., Beynon, C., Duffy, P., Evans-Brown, M, Mackridge, A, McCoy, E., Sumnalla, H., and, McVeigh, J. 2011. A Summary of the Health Harms of Drugs, Liverpool: Department of Health.
74. Kanayama, G., Hudson, J. I., and, Pope, H. G. 2010. Illicit Anabolic-Androgenic Steroid Use. Hormones and Behaviour, 58: 111-121.
75. Kannan, R. Y., Sankar, T. K., and, Ward, D. J. 2010. The Disaster of DIY Breast Augmentation. Journal of Plastic, Reconstructive & Aesthetic Surgery, 63: 100-101.
76. Keane, H. 2005. Diagnosing the Male Steroid User: Drug Use, Body Image and Disordered Masculinity. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine, 9 (2): 189-208.
77. Kemm, J., and, Close, A. 1995. Health Promotion Theory and Practice, London: Palgrave Macmillan.
78. Khoo, B. C. 1965. Paraffinoma. Plastic Reconstructive Surgery, 36: 101-110.
79. Kicman, A. T. 2008. Pharmacology of Anabolic Steroids. British Journal of Pharmacology, 154: 502-521.
80. Kramish, C. M., Meier, A., Carr, C., Enga, Z., James, A. S., and, Reedy, J. 2001. Health Behavior Changes after Colon Cancer: A Comparison of Findings from Face-to-Face and On-Line Focus Groups. Family and Community Health, 24 (3): 88-103.
81. Kunda, Z. 1987. Motivated Inference: Self Serving Generation and Evaluation of Causal Theories. Journal of Personality and Social Psychology, 53 (4): 636-647.
82. Kuzma, J. 2011. Web Vulnerability Study of Online Pharmacy Sites. Health and Social Care, 36: 20-34.
83. Langan, E. A., Nie, Z., and, Rhodes, L. E. 2010. Melanotropic Peptides: More Than Just Barbie Drugs and Sun-Tan Jabs?. British Journal of Dermatology, 163: 451-455.
84. Langan, E. A., Ramlogan, D., Jamieson, L. A., and, Rhodes, L. E. 2009. Change in Moles Linked to Use of Unlicensed Sun Tan Jab. British Medical Journal, 338: b277
85. Larance, B., Degenhardt, L., Copeland, J., and, Dillon, P. 2008. Injecting Risk Behaviour and Related Harm among Men Who Use Performance-and Image-Enhancing Drugs. Drug and Alcohol Review, 27 (6): 679-686.
86. Lenehan, P., Miller, T., and, Kemplay, R. 2004. Anabolic Steroids: A Guide for Users and Professionals, Manchester: Lifeline.
87. Liang, B. A., Mackey, T. K., and, Lovett, K. 2012. Emerging Dangers from Direct Botulinum Access and Use. Journal of Homeland Security and Emergency Management, 9 (1): 1547-7355.
88. Lupton, D. 1994. Moral Threats and Dangerous Desires: AIDS in the News Media, London: Taylor & Francis.
89. Lupton, D. 1995. Risk, London: Routledge.
90. Lupton, D. 1997. The Imperative of Health: Public Health and the Regulated Body, London: Sage.
91. Lupton, D., and, Tulloch, J. 2002. Life would be Pretty Dull without Risks: Voluntary Risk Taking and Its Pleasures. Health Risk and Society, 4: 113-124.
92. Mahiques-Santos, L. 2012. Melanotan. Actas Dermo-Sifiliograficas, 103: 257-259.
93. Mahne, C. 2002-09-04. "Implant Offers Tanning Revolution" (RealVideo). BBC. Retrieved 2012-11-26
94. Maropis, C., and, Yesalis, C. E. 1994. Intramuscular Abscess: Another Anabolic Steroid Danger. Physician and Sports Medicine, 22: 105-107.
95. Massumi, B. 1993. The Politics of Everyday Fear, Minneapolis: University of Minnesota Press.
96. McElrath, K., and, Connolly, D. 2006. Nalbuphine (Nubain): Non-Prescribed Use, Injecting, and Risk Behaviors for Bloodborne Viruses. Contemporary Drug Problems, 33: 321-340.
97. McVeigh, J., Beynon, C. M., and, Bellis, M. A. 2003. New Challenges for Agency Based Syringe Exchange Schemes: Analysis of 11 Years of Data (1991-2001) in Merseyside and Cheshire, United Kingdom. International Journal of Drug Policy, 14: 399-405.
98. McVeigh, J., Evans-Brown, M., and, Bellis, M. A. 2012. Human Enhancement Drugs and the Pursuit of Perfection. Adicciones, 24: 185-190.
99. Melanotan.org, 2009. "Melanotan.org". Melanotan.org. Retrieved 2009-08-29
100. Melia, P., Pipe, A., and, Greenberg, L. 1996. The Use of Anabolic-Androgenic Steroids by Canadian Students. Clinical Journal of Sports Medicine, 6 (1): 9-14.
101. Mello, S. 2012. Selling a Super Cosmeceutical: Contextualising Risk in Direct-to-Consumer Advertising of BOTOX® Cosmetic. Health. Risk & Society, 14 (4): 385-398.
102. Middleman, A. B., and, DuRant, R. H. 1996. Anabolic Steroid Use and Associated Health Risk Behaviours. Sports Medicine, 21: 251-255.
103. Midgley, S. J., Heather, N., Best, D., Henderson, D., McCarthy, S., and, Davies, J. B. 2000. Risk Behaviours for HIV and Hepatitis Infection among Anabolic-Androgenic Steroid Users. AIDS Care, 12: 163-170.
104. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., and, The PRISMA Group. 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Open Medicine, 3: 123-130.
105. Monaghan, L. F. 2001. Bodybuilding, Drugs and Risk, London: Routledge.
106. Monaghan, L. F. 2002. Vocabularies of Motive for Illicit Steroid Use amongst Bodybuilders. Social Science & Medicine, 55: 695-708.
107. Moss, H. B., Panzak, G. L., and, Tarter, R. E. 1992. Personality, Mood, and Psychiatric Symptoms among Anabolic Steroid Users. The American Journal on Addictions, 1: 315-324.
108. Mulcahey, M. K., Schiller, J. R., and, Hulstyn, M. J. 2010. Anabolic Steroid Use in Adolescents: Identification of Those at Risk and Strategies for Prevention. Physician and Sports Medicine, 38 (3): 105-113.
109. Munch, I. C., and, Hvolris, J. J. 2001. Body Building Aided by Intramuscular Injections of Walnut Oil. UgeskrLaeger, 163: 6758
110. Murphy, D., Murphy, M., and, Grainger, R. 2001. Self-castration. Irish Medical Journal, 170: 195
111. Nasr, J., and, Ahmad, J. 2009. Severe Cholestasis and Renal Failure Associated with the Use of the Designer Steroid Superdrol (Methasteron): A Case Report and Literature Review. Digestive Diseases and Sciences, 54: 1144-1146.
112. Naumann, M., So, Y., Argoff, C. E., Childers, M. K., Dykstra, D. D., Gronseth, G. S., Jabbari, B., and, Kaufmann, H. C. 2008. Assessment: Botulinum Neurotoxin in the Treatment of Autonomic Disorders and Pain (an Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 70 (19): 1707-1714.
113. Needle, R. H., Burrows, D., Friedman, S., Dorabjee, J., Touzé, G., Badrieva, L., Grund, J. P. C. 2004. Evidence for Action: Effectiveness of Community Based Outreach in Preventing HIV/AIDS among Injecting Drug Users, Geneva: World Health Organisation.
114. Nemoto, T., Operario, D., Keatley, J., Han, L., and, Soma, T. 2004. HIV Risk Behaviors among Male-to-Female Transgender Persons of Color in San Francisco. American Journal of Public Health, 94 (7): 1193-1199.
115. Nettleton, S., and, Bunton, R. 1995. " Sociological Critique of Health Promotion ". In The Sociology of Health Promotion, Edited by: Bunon, R., Nettleton, S. and Burrows, R. 41-59. London: Routledge.
116. Olivardia, R., Pope, H. G., and, Hudson, J. L. 2000. Muscle Dysmorphia in Male Weightlifters: A Case-Control Study. American Journal of Psychiatry, 157: 1291-1296.
117. Orizio, G., Merla, A., Schulz, P. J., and, Gelatti, U. 2011. Quality of Online Pharmacies and Websites Selling Prescription Drugs: A Systematic Review. Journal of Medical Internet Research, 13: e74
118. Orizio, G., Rubinelli, S., Schulz, P. J., Domenighini, S., Bressanelli, M., Caimi, L., and, Gelatti, U. 2010. Save 30% if You Buy Today, Online Pharmacies and the Enhancement of Peripheral Thinking in Consumers. Pharmacoepidemiol Drug Safety, 19: 970-976.
119. Orizio, G., Schulz, P., Domenighini, S., Caimi, L., Rosati, C., Rubinelli, S., and, Gelatti, U. 2009. Cyberdrugs: A Cross-Sectional Study of Online Pharmacies Characteristics. European Journal of Public Health, 19: 375-377.
120. Parkinson, A. B., and, Evans, N. A. 2006. Anabolic Androgenic Steroids: A Survey of 500 Users. Medicine and Science in Sports and Exercise, 38: 644-651.
121. Paurobally, D., Jason, F., Dezfoulian, B., and, Nikkels, A. F. 2011. Melanotan-Associated Melanoma. British Journal of Dermatology, 164: 1403-1405.
122. Perry, H. M., Wright, D., and, Littlepage, B. N. C. 1992. Dying to be Big: A Review of Anabolic Steroid Use. British Journal of Sports Medicine, 26 (4): 259-261.
123. Phillips, K. A., and, Diaz, S. F. 1997. Gender Differences in Body Dysmorphic Disorder. Journal of Nervous and Mental Disease, 185: 570-577.
124. Pope, H. G., Gruber, A. J., Choi, P., Olivardia, R., and, Phillips, K. A. 1997. Muscle Dysmorphia-An Underrecognized Form of Body Dysmorphic Disorder. Psychosomatics, 38: 548-557.
125. Pope, H. G., and, Katz, D. L. 1988. Affective and Psychotic Symptoms Associated with Anabolic Steroid Use. The American Journal of Psychiatry, 145: 487-490.
126. Pope, H. G. Jr., Katz, D. L., and, Hudson, J. I. 1993. Anorexia Nervosa and "Reverse Anorexia" Among 108 Male Bodybuilders. Comprehensive Psychiatry, 34: 406-409.
127. Pope, H. G., Philips, K. A., and, Olivardia, R. 2000. The Adonis Complex, New York: Simon & Schuster.
128. Pope, C. G., Pope, H. G., Menard, W., Fay, C., Olivardia, R., and, Phillips, K. A. 2005. Clinical Features of Muscle Dysmorphia among Males with Body Dysmorphic Disorder. Body Image, 2: 395-400.
129. Pupka, A., Sikora, J., Mauricz, J., Cios, D., and, Płonek, T. 2009. The Usage of Synthol in the Body Building. [In Polish]. Polimery w Medycynie, 39: 63-65.
130. Reich, W., Compton, W. M., Horton, J. C., Cottler, L. B., Cunningham-Williams, R. M., Booth, R., Singer, M. 2002. Injection Drug Users Report Good Access to Pharmacy Sale of Syringes. Journal of the American Pharmaceutical Association, 42 (6 Suppl. 2): S68-S72.
131. Restrepo, C. S., Artunduaga, M., Carrillo, J. A., Rivera, A. L., Ojeda, P., Martinez-Jimenez, S., Manzano, A. C., and, Rossi, S. E. 2009. Silicone Pulmonary Embolism: Report of 10 Cases and Review of the Literature. Journal of Computer Assisted Tomography, 33 (2): 233-237.
132. Rhodes, T., Barnard, M., Fountain, J., Hariga, F., Romo Avilés, N., Vicente, J., and, Weber, U. 2001. Injecting Drug Use, Risk Behaviour and Qualitative Research in the Time of AIDS, EMCDDA. Luxembourg: Office for Official Publications of the European Communities.
133. Rhodes, L., and, Langan, E. 2011. Melanotropic Peptides: What Exactly Is Meant by Melanotan?. Acta Dermato-Venereologica, 91: 377-378.
134. Rich, J. D., Foisie, C. K., Towe, C. W., Dickinson, B. P., McKenzie, M., and, Salas, C. M. 1999. Needle Exchange Program Participation by Anabolic Steroid Injectors, United States 1998. Drug and Alcohol Dependence, 56: 157-160.
135. Room, R. 2011. Addiction and Personal Responsibility as Solutions to the Contradictions of Neolibral Consumerism. Critical Public Health, 21 (2): 141-151.
136. Rose, N. 1989. Governing the Soul: The Shaping of the Private Self, London: Routledge.
137. Ross, J. 2011. Explosion of Steroid Use Fuelled by Reverse Anorexia. Available at http://www.scotsman.com/news/explosion-of-steroid-use-fuelled-by- reverse-anorexia-1-1498568 [Accessed 10 September 2012]
138. Saba, V. K., and, McCormick, K. A. 2001. Essentials of Computers for Nurses: Informatics for the New Millennium, New York: McGraw-Hill.
139. Schnetzler, G., Banks, I., Kirby, M., Zou, K. H., and, Symonds, T. 2010. Characteristics, Behaviors, and Attitudes of Men Bypassing the Healthcare System When Obtaining Phosphodiesterase Type 5 Inhibitors. Journal of Sexual Medicine, 7: 1237-1246.
140. Schwerin, M. J., and, Corcoran, K. J. 1996. Beliefs about Steroids: User Vs. Non-User Comparisons. Drug and Alcohol Dependence, 40: 221-225.
141. Seedhouse, D. 2000. Health Promotion Philosophy, Prejudice and Practice, New York: Wiley.
142. Slovic, P., Fishhoof, B., and, Lichtenstein, S. 1982. Why Study Risk Perception?. Risk Analysis, 2 (2): 83-93.
143. Smith, N. 2010. Incorporating Local Knowledge(s) in Health Promotion. Critical Public Health, 20 (2): 211-222.
144. Smith, A., and, Stewart, B. 2012. Body Conceptions and Virtual Ethnopharmacology in an Online Bodybuilding Community. Performance Enhancement & Health, 1: 35-38.
145. Stewart, L. A., and, Clarke, M. J. 1995. Practical Methodology of Meta-Analyses (Overviews) Using Updated Individual Patient Data. Cochrane Working Group. Statistics in Medicine, 14: 2057-2079.
146. Stieglitz, K. A. 2010. Development, Risk, and Resilience of Transgender Youth. Journal of the Association of Nurses, 21: 192-206.
147. Strange, P. 2009. "Scientists: Heroes or Villains? What We Can Learn from the Barbie Drug." Accessed September 4, 2012. http://www.lablit.com/ article/498
148. Thestrup-Pedersen, K. 2011. Reply to the Letter by Langan Rhodes. Acta Dermato-Venereologica, 91: 378
149. Toy, B. R., and, Frank, P. J. 2003. Review Outbreak of Mycobacterium Abscessus Infection after Soft Tissue Augmentation. Dermatological Surgery, 29 (9): 971-973.
150. Trenton, A. J., and, Currier, G. W. 2005. Behavioural Manifestations of Anabolic Steroid Use. CNS Drugs, 19: 571-595.
151. Tricker, R., O'Neill, M. R., and, Cook, D. 1989. The Incidence of Anabolic Steroid Use Among Competitive Bodybuilders. Journal of Drug Education, 19 (4): 313-325.
152. Ugwu, S. O., Blanchard, J., Dorr, R. T., Levine, N., Brooks, C., Hadley, M. E., Aickin, M., and, Hruby, V. J. 1997. Skin Pigmentation and Pharmacokinetics of Melanotan-I in Humans. Biopharmaceutics & Drug Disposition, 18: 259-269.
153. Van Hout, M. C., and T. Bingham. 2013. "Silk Road, the Virtual Drug Marketplace: A Single Case Study of User Experiences." International Journal of Drug Policy. March 1. pii: S0955-3959(13)00006-6. doi: 10.1016/j.drugpo.2013.01.005. [Epub ahead of print]
154. Walker, D. M., and, Joubert, H. E. 2011. Attitudes of Injecting Male Anabolic Androgenic Steroid Users to Media Influence, Health Messages and Gender Constructs. Drug and Alcohol Today, 11 (2): 65-70.
155. Wessells, H., Levine, N., Hadley, M. E., Dorr, R., and, Hruby, V. 2000. Melanocortin Receptor Agonists, Penile Erection, and Sexual Motivation: Human Studies with Melanotan II. International Journal of Impotence Research, 12: 74-79.
156. Williams, H., Rcmedios, A., Rooney, J., and, Hanstock, R. 2000. Nalbuphine Dependence: A Brief Report from the UK. Irish Journal of Psychological Medicine, 17: 20-21.
157. Wright, S., Grogan, S., and, Hunter, G. 2000. Motivations for Anabolic Steroid Use among Bodybuilders. Journal of Health Psychology, 5: 566-571.
158. Xavier, J. M., Bobbin, M., Singer, B., and, Budd, E. 2005. A Needs Assessment of Transgendered People of Color Living in Washington, DC. International Journal of Transgenderism, 8: 31-47.
159. Yates, W. R., Perry, P., and, Murray, S. 1992. Aggression and Hostility in Anabolic Steroid Users. Biological Psychiatry, 31: 1232-1234.
160. Yesalis, C. E., and, Bahrke, M. S. 1995. Anabolic-Androgenic Steroids: Current Issues. Sports Medicine, 19: 326-340.
161. Zamora, A. C., Collard, H. R., Barrera, L., Mendoza, F., Webb, W. R., and, Carrillo, G. 2009. Silicone Injection Causing Acute Pneumonitis: A Case Series. Lung, 187 (4): 241-244.